DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 04 · Volume 5 · July 1972 DOI: 10.1055/s-002-15208

Originalarbeiten

  • 177
    Coper, H.; Deyhle, G.; Fähndrich, Ch.; Fähndrich, E.; Rosenberg, L.; Strauss, S.; Blum, A.; Dufour, H.:

    Excretion of Vanillyl-Mandelic Acid, Homovanillic Acid, N-Methyl-Nicotinamide, and N-Methyl-2-Pyridone-5-Carboxamide in Urine of Voluntary Test Persons and Psychiatric Patients Before and After Administration of Methionine

  • 187
    Lidberg, L.:

    The Effect of Syntocinon® on Patients Suffering from Impotence

  • 191
    Park, S.; Burdock, E. I.; Gershon, S.:

    Importance of Adequate Dosage Determination of Drug Efficacy: Trial of a New Butyrophenone Compound on Acute Schizophrenics*

  • 198
    Strian, F.; Micheler, E.; Benkert, O.:

    Tremor Inhibition in Parkinson Syndrome After Apomorphine Administration Under L-Dopa and Decarboxylase-Inhibitor Basic Therapy

  • 205
    Rapp, W.:

    Preliminary Study of Perphenazine Enanthate in the Treatment of Chronic Schizophrenia

  • 215
    Voelkel, A.:

    Medikamentenmißbrauch – Anonyme präklinische Selbstbehandlung

    Drug abuse as anonymous preclinical self-therapy
  • 219
    Hesse, G.:

    N-Phenyl-N-benzyl-4-amino-1-methyl-piperidin-hydrochloride (Bamipine) combined with 1-Cyclohexyl-1-methyl-2-methyl-amino-ethane (CHP) as a psychotropic drug for the interval and terminal treatment of depressive syndroms.

    N-Phenyl-N-benzyl-4-amino-1-methylpiperidin-hydrochlorid (Bamipine) kombiniert mit 1-Cyclohexyl-1-methyl-2-methyl-amino-äthan (CHP)* als Psychopharmakon zur Intervall- und Terminalbehandlung depressiver Syndrome